Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAM-760 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | active arm/healthy young |
| 2 | PLACEBO_COMPARATOR | placebo arm |
| 3 | OTHER | ketoconazole interaction evaluation |
| Name | Type | Description |
|---|---|---|
| SAM-760 | DRUG | SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day |
| Placebo of SAM-760 | DRUG | SAM-760 matching placebo capsule, single dose, 1 day, |
| ketoconazole | DRUG | Ketoconazole oral tablets, 200 mg bid, 14 days |
Inclusion Criteria: * Men or women of non-childbearing potential aged 18 to 50 years inclusive (healthy young subjects) and \> 65 years (healthy elderly subjects) at screening. * Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight \>= 50 kg. Exclusion Criteria: * Presence or hist...
SAM-760 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other. It is not approved and remains under clinical investigation.
The molecular target of SAM-760 has not been disclosed in available information. Therefore, its mechanism of action is not specified. The drug is being studied for its safety and tolerability in healthy subjects, but the specific biological target is not publicly detailed.
SAM-760 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is responsible for the clinical development of this investigational small molecule drug.
SAM-760 is in Phase 1 clinical development. A Phase 1 study evaluating the safety and tolerability of single oral doses of SAM-760 in healthy subjects has been completed. The drug is investigational and has not received regulatory approval.
SAM-760 has one completed clinical trial, identified as NCT00948662. This Phase 1 study evaluated the safety and tolerability of single oral doses of SAM-760 in healthy subjects. The trial was conducted in France, enrolled 124 participants, and was randomized, double-blind, and placebo-controlled.
No alternative names for SAM-760 have been identified in available information. The drug is known only by its code name SAM-760 in clinical trial records. It is not associated with any other marketed or investigational drug name.